title: Use of dorzolamide for patients with X-linked retinoschisis.
abstract: OBJECTIVE
  To determine the value of a topical carbonic anhydrase inhibitor for the treatment of foveal lesions in patients with X-linked retinoschisis (XLRS).
  
  
  METHODS
  Eight patients with XLRS and foveal cystic-appearing spaces by fundus examination and by optical coherence tomography (OCT) were treated with a topical form of carbonic anhydrase inhibitor. Changes in "foveal thickness" and "foveal zone thickness" were measured by OCT, and changes of best-corrected visual acuity were measured by Early Treatment Diabetic Retinopathy Study (ETDRS) charts.
  
  
  RESULTS
  Seven of eight patients treated with 2% dorzolamide had a noticeable reduction in foveal thickness as well as cystic-appearing spaces by OCT. This reduction was found in both eyes in four of these patients and in one eye in one patient after 1 month of treatment. After an additional 1 month to 2 months of the same treatment regimen, two additional patients also had a noticeable reduction in foveal thickness as well as cystic-appearing spaces. Of these seven patients who had an improvement shown by OCT with treatment, five also had improvement of their visual acuity by >or=7 letters in at least one eye on ETDRS charts.
  
  
  CONCLUSIONS
  The present study shows the efficacy of topical dorzolamide for treating foveal cystic-appearing lesions in patients with XLRS.
authors.affiliation: Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois 60612, USA.
authors.forename: Marsha A
authors.initials: MA
authors.lastname: Apushkin
authors.forename: Gerald A
authors.initials: GA
authors.lastname: Fishman
mesh_terms: D000287:Administration, Topical; D000328:Adult; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use*; D003560:Cysts / Q000175:diagnosis / Q000188:drug therapy; D005584:Fovea Centralis / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D011446:Prospective Studies; D041441:Retinoschisis / Q000175:diagnosis / Q000188:drug therapy*; D013449:Sulfonamides / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D009883:Ophthalmic Solutions; D013449:Sulfonamides; D013876:Thiophenes; C062765:dorzolamide